Outlook Therapeutics Stock Forecast
NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 0.597 -0.32%
OTLK analyst consensus
Consensus (4 analysts)
none
Avg. price target
$5.03+739.87%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Outlook Therapeutics (2026-10-08), 3 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $5.03, with a high estimate of $10.50 and a low estimate of $1.60. The average target implies upside of 739.9% from the current price of $0.5989.
The spread between the highest and lowest targets is 556.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for OTLK.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 75% |
| Hold | 1 | 25% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.60 | +167.16% |
| Average target | $5.03 | +739.87% |
| High target | $10.50 | +1653.21% |